Cervasi B, Paiardini M, Serafini S, Fraternale A, Menotta M, Engram J, Lawson B, Staprans S I, Piedimonte G, Perno C F, Silvestri G, Magnani M
Institute of Biochemistry, University of Urbino, Urbino, Italy.
J Virol. 2006 Nov;80(21):10335-45. doi: 10.1128/JVI.00472-06.
A major limitation of highly active antiretroviral therapy is that it fails to eradicate human immunodeficiency virus (HIV) infection due to its limited effects on viral reservoirs carrying replication-competent HIV, including monocytes/macrophages (M/M). Therefore, therapeutic approaches aimed at targeting HIV-infected M/M may prove useful in the clinical management of HIV-infected patients. In previous studies, we have shown that administration of fludarabine-loaded red blood cells (RBC) in vitro selectively induces cell death in HIV-infected M/M via a pSTAT1-dependent pathway. To determine the in vivo efficacy of this novel therapeutic strategy, we treated six naturally simian immunodeficiency virus (SIV)-infected sooty mangabeys (SMs) with either 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) only, fludarabine-loaded RBC only, or PMPA in association with fludarabine-loaded RBC. The rationale of this treatment was to target infected M/M with fludarabine-loaded RBC at a time when PMPA is suppressing viral replication taking place in activated CD4+ T cells. In vivo administration of fludarabine-loaded RBC was well tolerated and did not induce any discernible side effect. Importantly, addition of fludarabine-loaded RBC to PMPA delayed the rebound of viral replication after suspension of therapy, thus suggesting a reduction in the size of SIV reservoirs. While administrations of fludarabine-loaded RBC did not induce any change in the CD4+ or CD8+ T-cell compartments, we observed, in chronically SIV-infected SMs, a selective depletion of M/M expressing pSTAT1. This study suggests that therapeutic strategies based on the administration of fludarabine-loaded RBC may be further explored as interventions aimed at reducing the size of the M/M reservoirs during chronic HIV infection.
高效抗逆转录病毒疗法的一个主要局限性在于,由于其对携带具有复制能力的人类免疫缺陷病毒(HIV)的病毒储存库(包括单核细胞/巨噬细胞(M/M))的作用有限,无法根除HIV感染。因此,旨在靶向HIV感染的M/M的治疗方法可能对HIV感染患者的临床管理有用。在先前的研究中,我们已经表明,体外给予负载氟达拉滨的红细胞(RBC)通过pSTAT1依赖性途径选择性地诱导HIV感染的M/M细胞死亡。为了确定这种新型治疗策略的体内疗效,我们用仅9-[2-(R)-(膦酰甲氧基)丙基]腺嘌呤(PMPA)、仅负载氟达拉滨的RBC或PMPA与负载氟达拉滨的RBC联合治疗了六只自然感染猿猴免疫缺陷病毒(SIV)的黑猩猩(SM)。这种治疗的基本原理是在PMPA抑制活化的CD4+T细胞中发生的病毒复制时,用负载氟达拉滨的RBC靶向感染的M/M。负载氟达拉滨的RBC的体内给药耐受性良好,没有诱导任何可察觉的副作用。重要的是,在PMPA中添加负载氟达拉滨的RBC延迟了治疗暂停后病毒复制的反弹,从而表明SIV储存库的大小有所减少。虽然负载氟达拉滨的RBC给药没有引起CD4+或CD8+T细胞区室的任何变化,但我们在慢性SIV感染的SM中观察到,表达pSTAT1的M/M有选择性的耗竭。这项研究表明,基于负载氟达拉滨的RBC给药的治疗策略可能作为旨在减少慢性HIV感染期间M/M储存库大小的干预措施而得到进一步探索。